Please login to the form below

Not currently logged in
Email:
Password:

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn

Sanofi is in the midst of a shakedown of its business prompted by a decline in sales of its diabetes blockbuster Lantus (insulin glargine) and the failure of some other products

Latest news

  • Type 2 diabetes can be reversed in just four months, say researchers Type 2 diabetes can be reversed in just four months, say researchers

    calorie intake by 500 to 750 per day and continued use of glucose-controlling drugs (metformin, acarbose and in some cases basal insulin) to closely manage blood sugar levels. ... According to lead investigator Hertzel Gerstein, the team chose to use

  • Sanofi wins EU approval for new diabetes combination Suliqua Sanofi wins EU approval for new diabetes combination Suliqua

    The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo

  • Sanofi launches insulin combo Soliqua in US Sanofi launches insulin combo Soliqua in US

    Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination

  • Lilly and Boehringer launch first Lantus clone Basaglar in US Lilly and Boehringer launch first Lantus clone Basaglar in US

    Eli Lilly and Boehringer Ingelheim have launched their Basaglar copy at a 15% discount to Lantus (insulin glargine), which is already facing tough competition from other insulin products such as Novo ... We know that starting insulin can be a challenging

  • FDA clears rival diabetes combos from Sanofi and Novo Nordisk FDA clears rival diabetes combos from Sanofi and Novo Nordisk

    In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin degludec) and market-leading GLP-1 agonist Victoza (liraglutide). ... In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan)

More from news
Approximately 23 fully matching, plus 105 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the

  • Pharma deals during February 2013 Pharma deals during February 2013

    Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics